# FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

> **NCT05020483** · PHASE2 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Cardiac Disease

## Interventions

- **DRUG:** FEIBA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05020483
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Patient population changed and no subjects eligible for the study.
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020483, "FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05020483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*